TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06990399: A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) -

Sponsor: Kodiak Sciences Inc · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 600 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,843,120

Rescue Site Savings

+$7,165,888

Unlock Full NCT06990399 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06990399 Rescue Dossier →